News about 'Front Lines of TB R&D'

7 Nov 2010
NC001 Today, the TB Alliance announced the first clinical trial to test multiple new TB drugs in combination; the trial is known as New Combination 1 (NC001).The experimental regimen undergoing testing in this trial consists of experimental TB drugs PA-824, Moxifloxacin, and Pyrazinamide, an...
3 Nov 2010
Typical Lab This is part 2 of Lisan Parker’s photo collection from her recent trip to South Africa as part of her new role as Research Liason to the KwaZulu-Natal Research Institute for Tuberculosis and HIV ( click here to view part 1 ): These are additional pictures taken from a tour of additional...
18 Oct 2010
Chest X-Rays Lisan Parker, who is transitioning into her new role as Research Liason to the KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), filed this report on her recent trip to South Africa: As part of my trip to South Africa as Research Liaison to K-RITH, I and colleagues of...
27 Sep 2010
Dear readers, please accept our apologies for missing the past couple of Tuesday R&D posts on the latest developments and meetings taking place in the TB R&D arena. There have been several important changes afoot and we are in the process of hammering out the final details so things will be...
24 Aug 2010
A distinct whole-blood 86-gene transcriptional signature of active TB (Figure 2 in the paper) Last week, a paper was published in Nature by Matthew Berry, Christine Graham et al. which received a fair amount of notice. The authors presented data identifying a probable TB gene signature in people...
19 Aug 2010
This story originally appeared on Reuters here: http://www.reuters.com/article/idUSTRE67H3OH20100818 A patient who tested positive for extreme drug resistant tuberculosis (XDR-TB) awaits treatment at a rural hospital at Tugela Ferry in South Africa's impoverished KwaZulu Natal province, in this...
18 Aug 2010
Cameron Kaiser, MD Last week , Dr. Kaiser shared his thoughts and perspectives as a medical doctor on the current state of TB drug regimens. This week he shares specific ideas on how TB drug R&D could be improved. From a clinical perspective, I think there are some less obvious aims to optimize...
16 Aug 2010
This article originally appeared on Citizen News Service. Click here to read the original post. by Shobha Shukla Open Forum 4 The Open Forum 4 on key issues in tuberculosis (TB) drug development is all set to begin in Addis Ababa, Ethiopia (18-19 August 2010). This Open Forum 4, will raise and...
16 Aug 2010
Review of JACS Communication, “Catalytic Asymmetric Synthesis of R207910″ By Christopher Cooper, Director of Chemistry, TB Alliance Retrosynthetic Approach to TMC207 (click to view larger) The novel antitubercular agent TMC207 ( Tibotec , a Johnson & Johnson company) represents an impressive...
11 Aug 2010
Cameron Kaiser, MD Viewpoint by Cameron Kaiser, MD, Medical Consultant for Tuberculosis, Riverside County Department of Public Health, California and guest WGND blogger. Antibiotics are, to the typical patient, always the quick fix. Despite our best attempts to convince them that their viral...
10 Aug 2010
2.1 Å DNA gyrase complex with GSK299423 (Figure 2 from paper) This week we reposted an article from DailyFinance.com regarding a new antibactierial compound from GlaxoSmithKline (GSK) . GSK has recently published a Nature paper describing the 2.1 angstom crystal structure of Staphylococcus aureus...
3 Aug 2010
Cofactor F420 Structure The need for the identification of novel TB drug targets and biomarkers has been highlighted in a few of our posts over the last several months. A recent epublication (online manuscript before print) in the Journal of Bacteriology by Jeremy D. Selengut and Daniel H. Haft...
21 Jul 2010
TAG 2010 Pipeline Report Treatment Action Group (TAG) recently released their TAG 2010 Pipeline Report (.pdf – 1,700kb), an annual report that explores the progress and overall state of drug development in the fields of HIV, Tuberculosis, and Viral Hepatitis. The report covers the development of...
6 Jul 2010
Cepheid® MTB/RIF Assay cartridge In our latest ‘Sanatorium Files’ post ‘Diagnosis Dilemma’ , we commented on the current advances in TB diagnostics. We’re following up on this theme for the next couple of posts to share the scientific data supporting some of the most promising of these new...
6 Jul 2010
TB Alliance and DNDi Enter into a Unique Collaboration New Potential TB Drugs to be Investigated Against Multiple Neglected Diseases A Unique Collaboration: TB Alliance and DND i Enter Cross-Disease License Agreement to Speed Development of Novel Therapies New York, United States and Geneva,...

Pages